Ocrelizumab/hyaluronidase
id:
ocrelizumab-hyaluronidase-223-722527
title:
Ocrelizumab/hyaluronidase
text:
Ocrelizumab/hyaluronidase, sold under the brand name Ocrevus Zunovo, is a fixed-dose combination medication used for the treatment of multiple sclerosis. It contains ocrelizumab, a recombinant humanized monoclonal antibody directed at CD20; and hyaluronidase, an endoglycosidase. It is taken by subcutaneous injection. Ocrelizumab/hyaluronidase was approved for medical use in the United States in September 2024.
brand slug:
wiki
category slug:
encyclopedia
description:
Combination medication
original url:
https://en.wikipedia.org/wiki/Ocrelizumab/hyaluronidase
date created:
2024-09-13T23:11:42Z
date modified:
2024-09-14T05:45:16Z
main entity:
image:
fields total:
13
integrity:
14